Matches in Wikidata for { <http://www.wikidata.org/entity/Q73640509> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- Q73640509 description "artículu científicu espublizáu n'abril de 2000" @default.
- Q73640509 description "im April 2000 veröffentlichter wissenschaftlicher Artikel" @default.
- Q73640509 description "scientific article published on 01 April 2000" @default.
- Q73640509 description "wetenschappelijk artikel" @default.
- Q73640509 description "wüsseschaftlicher Artikel, wo im April 2000 veröffentlicht worden isch" @default.
- Q73640509 description "наукова стаття, опублікована у квітні 2000" @default.
- Q73640509 name "A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study" @default.
- Q73640509 name "A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study" @default.
- Q73640509 type Item @default.
- Q73640509 label "A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study" @default.
- Q73640509 label "A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study" @default.
- Q73640509 prefLabel "A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study" @default.
- Q73640509 prefLabel "A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study" @default.
- Q73640509 P1433 Q73640509-17A56474-2E91-4D72-BCAA-B312580F702F @default.
- Q73640509 P1476 Q73640509-B738DCBA-EDFD-4CDD-A05C-43E3DAA1CAB0 @default.
- Q73640509 P2093 Q73640509-0421465B-74FF-4EE9-A83C-E81D13FF5CAD @default.
- Q73640509 P2093 Q73640509-299A0FA1-70B1-4CD2-A6F3-ABA9D0DE81FC @default.
- Q73640509 P2093 Q73640509-32F4B672-CACD-4C59-86FF-2A92FB1D42E9 @default.
- Q73640509 P2093 Q73640509-3E67DA9A-64ED-4552-8A15-3B930DC49FAB @default.
- Q73640509 P2093 Q73640509-5A612DC8-C6A7-4FA6-B93D-E2D534AE96E8 @default.
- Q73640509 P2093 Q73640509-618795D6-4CC2-462D-8572-2ECAE3A70DDA @default.
- Q73640509 P2093 Q73640509-67C4FE5D-9C5D-44C1-BF75-F7FEB58E6EC4 @default.
- Q73640509 P2093 Q73640509-683B5B47-9EDF-446D-B06A-8C32BBCE6DE6 @default.
- Q73640509 P2093 Q73640509-C8A2BD9E-69BB-4F57-9F77-22D6A251329E @default.
- Q73640509 P2093 Q73640509-D5063B16-CA1C-40D9-8A55-4B6AB8213CBE @default.
- Q73640509 P2093 Q73640509-E047EF77-1A4C-4E88-BA16-BD40D8244B71 @default.
- Q73640509 P2093 Q73640509-E81FE8CF-6869-45E7-8622-F67649D46C91 @default.
- Q73640509 P2093 Q73640509-F89CD6F6-DA8D-4521-87E5-4D1C6C729183 @default.
- Q73640509 P304 Q73640509-AA86F5A7-C1BD-4A5C-AE99-F97BD8D736DC @default.
- Q73640509 P31 Q73640509-1BFB1223-896A-4794-B6B2-9E1660FFC6A5 @default.
- Q73640509 P356 Q73640509-A851B046-CE69-43D6-B31F-9F9264E48254 @default.
- Q73640509 P433 Q73640509-7DBA3295-2E5A-4296-8908-57CC785B3CF4 @default.
- Q73640509 P478 Q73640509-FE09BE49-13EA-4AFE-9F73-5CB78713A4B0 @default.
- Q73640509 P577 Q73640509-02FCFCC8-8BAD-4390-A7E7-2E2D9CFFABD8 @default.
- Q73640509 P698 Q73640509-EA7A6ED8-D0DC-41BC-B43A-86B7FBE7C56D @default.
- Q73640509 P921 Q73640509-389CE539-62E3-49F1-9A99-D00C7FA05C5E @default.
- Q73640509 P921 Q73640509-477CE725-08B8-42AA-954C-CB87EE934165 @default.
- Q73640509 P921 Q73640509-C05D781B-ACD1-4046-9CEF-696CC3962093 @default.
- Q73640509 P356 10428190009089437 @default.
- Q73640509 P698 10752988 @default.
- Q73640509 P1433 Q6534493 @default.
- Q73640509 P1476 "A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study" @default.
- Q73640509 P2093 "A M Lynott" @default.
- Q73640509 P2093 "A P Caviles" @default.
- Q73640509 P2093 "F J Giles" @default.
- Q73640509 P2093 "G Y Tee" @default.
- Q73640509 P2093 "I Aydogdu" @default.
- Q73640509 P2093 "I Supandiman" @default.
- Q73640509 P2093 "J Shan" @default.
- Q73640509 P2093 "M R Chasen" @default.
- Q73640509 P2093 "S Chen" @default.
- Q73640509 P2093 "S H Advani" @default.
- Q73640509 P2093 "T Y Chaoj" @default.
- Q73640509 P2093 "Z Aziz" @default.
- Q73640509 P2093 "Z Fahed" @default.
- Q73640509 P304 "367-377" @default.
- Q73640509 P31 Q13442814 @default.
- Q73640509 P356 "10.3109/10428190009089437" @default.
- Q73640509 P433 "3-4" @default.
- Q73640509 P478 "37" @default.
- Q73640509 P577 "2000-04-01T00:00:00Z" @default.
- Q73640509 P698 "10752988" @default.
- Q73640509 P921 Q180983 @default.
- Q73640509 P921 Q212272 @default.
- Q73640509 P921 Q5113990 @default.